Background--Cardiomyocytes that differentiate from pluripotent stem cells (PSCs) provide a crucial cellular resource for cardiac regeneration. The mechanisms of mitochondrial metabolic and redox regulation for efficient cardiomyocyte differentiation are, however, still poorly understood. Here, we show that inhibition of the mitochondrial permeability transition pore (mPTP) by Cyclosporin A (CsA) promotes cardiomyocyte differentiation from PSCs.
I
f not treated immediately, myocardial infarction can lead to permanent and irreversible loss of cardiomyocytes in the corresponding region of the heart. Substantial damage in the myocardium can manifest as reduced structural and functional capacity of the blood-pumping organ, ultimately giving rise to congestive heart failure. 1 Many researchers and clinicians are extensively investigating the feasibility of using putative cardiac stem cells and cardiomyocytes derived from adult and pluripotent stem cells (PSCs) for the functional recovery of damaged hearts. [2] [3] [4] [5] Thus far, replacing damaged cardiomyocytes with fresh and healthy cardiomyocytes by direct implantation is the predominate method among several potential approaches for cardiac regeneration. 6, 7 However, major hurdles remain that hinder cardiac stem cell therapy from becoming a clinically applicable strategy for restoring cardiac function. 2, 8, 9 Among these major obstacles, obtaining a sufficient amount of purified cardiomyocytes from PSCs is of the greatest importance. PSCs such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have emerged as an attractive resource for generating de novo cardiomyocytes. Specifically, Flk1
+ mesodermal precursor cells (MPCs), which can be obtained by differentiating PSCs, were previously identified as cardiovascular progenitors. Flk1 + MPCs can give rise to cardiomyocytes, endothelial cells (ECs), hematopoietic cells (HCs), and mural cells. [10] [11] [12] [13] [14] Among several cardiomyogenic molecules, we have been interested in Cyclosporin A (CsA), which is best known as an immunosuppressive agent. Surprisingly, it has been reported recently that CsA induces cardiomyogenesis, 15, 16 but the exact mechanism of CsA's effects in cardiomyogenesis is unknown.
CsA inhibits the mitochondrial permeability transition pore (mPTP) via binding to peptidyl-prolyl cis-trans-isomerase, also known as cyclophilin D, which is a matrix protein of mPTP. The mPTP is a nonselective pore that is permeable to any molecule of <1.5 kDa in size. 17, 18 The mPTPs open within the mitochondrial inner membrane under pathologic conditions such as mitochondrial calcium overload. 18, 19 Previous studies focused mainly on showing that pharmacologic inhibition of mPTP by CsA has a cardioprotective effect in an ischemia-reperfusion injury model. 17, 18 However, the role of mPTP inhibition in stem cell differentiation and its downstream signaling has not been clearly elucidated.
Concomitant increase of myofibrils and mitochondria is a key process of cardiomyocyte differentiation from PSCs. Specifically, development of mitochondrial oxidative metabolic capacity in cardiomyocytes is essential to providing the energy necessary to sustain the beating function. Therefore, the connection between transcriptional and metabolic regulation is important for cardiomyocyte specification and differentiation, and a nucleus-mitochondria interaction is required to translate signals that regulate cardiomyogenesis. 20 Although previous studies reported that mitochondrial function and oxidative metabolism have some correlation with the differentiation of cardiomyocytes, [20] [21] [22] [23] [24] [25] the mechanism by which mitochondrial oxidative metabolism is regulated and the link between cardiomyogenesis and mitochondrial function are still poorly understood. Additionally, reactive oxygen species (ROS) modulate the differentiation of cardiomyocytes from ESCs, [26] [27] [28] [29] [30] but the exact role of redox signaling in PSCderived cardiomyocyte differentiation remains controversial. 31, 32 In the present study, we demonstrate that CsA promotes differentiation of functional cardiomyocytes from PSCderived Flk1 + MPCs by inhibition of mPTP. This increase in differentiation appears to result from activation of mitochondrial oxidative metabolism. In addition, we found that antioxidant treatment augmented the cardiomyogenic effect of CsA. These data thus constitute novel evidence that activation of mitochondrial oxidative metabolism via inhibition of mPTP and subsequent changes in redox signaling pathways are key factors in PSC fate determination toward the cardiac lineage. Our findings suggest that modulation of mPTP and redox signaling could be a compelling target for cardiac stem cell therapy in the field of regenerative medicine.
Methods
Mouse and Human PSC and OP9 Cell Culture EMG7 mouse ESCs, which have a-myosin heavy chain (MHC) promoter-driven enhanced green fluorescent protein (GFP) gene, E14Tg2a ESCs and OP9 cells were generated and maintained as described previously. 11, 33, 34 Mouse iPSCs derived from FVB strain was obtained through a generous gift from Drs Hyun-Jai Cho and Hyo-Soo Kim (Seoul National University Hospital) and prepared as described previously.
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H9 human ESCs were purchased from the ATCC. We received approval from the institutional review board of KAIST to perform the experiments using human ESCs.
Induction of Mouse PSC-Derived Flk1 + MPCs and Cardiomyocytes
For induction of Flk1 + MPCs, ESCs, and iPSCs were cultured without LIF (leukemia inhibitory factor) and plated on a 0.1% gelatin-coated dish at cell density 1 to 1.5910 3 Matrigel-coated dishes at a density of 10.0910 4 cells/cm 2 in mouse embryonic fibroblast conditioned medium (MEF-CM) with 4 ng/mL basic fibroblast growth factor (bFGF) for 2 to 3 days before induction. To induce cardiomyocyte differentiation, we replaced MEF-CM with RPMI+B27 medium (RPMI1640, 2 mmol/L L-glutamine, 91 B27 supplement without insulin) with 100 ng/mL of activin A (R&D Systems) for 24 hours, followed by 10 ng/mL of human bone morphogenetic protein 4 (BMP4; R&D Systems) and 10 ng/mL human bFGF for 4 days. The culture medium was subsequently changed with RPMI+B27 supplemented with 100 ng/ mL of Dickkopf-related protein 1 (Dkk1, R&D Systems) for 2 days. At day 7, the culture medium was changed to RPMI+B27 with vascular endothelial growth factor (VEGF, R&D Systems). The medium was changed every 1 to 2 days. Beating cardiomyocytes were observed on days 8 to 9.
Culture of H9C2 Cardiac Cell Line
The rat cardiac cell line H9C2 was purchased from the ATCC. The cells were grown in DMEM (Welgene) supplemented with 10% FBS (Welgene) and antibiotics (Invitrogen). Before confluence, cells were split, plated at a lower density in culture dishes in 10% FBS culture medium and cultured for 1 to 2 days. Cells were then incubated in DMEM (welgene) supplemented with 1% FBS for myogenic differentiation. 37 The culture medium was replaced every 2 days.
Reagents
CsA (a gift from Novartis Pharma, Korea), NIM811 (N-methyl-4-isoleucine-CsA, a gift from Novartis Pharma, Swiss Basel), FK506 (Sigma Aldrich), carbonyl cyanide-p-trifluoromethoxy phenylhydrazone (FCCP, Abcam), 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox, Sigma Aldrich), IWP-2, IWP-4 (Stemgent) and SB431542 (Sellekchem) were dissolved in dimethyl sulfoxide (DMSO, Sigma Aldrich). N-acetyl-Lcysteine (NAC, Sigma Aldrich) and tert-butyl hydroperoxide (tBHP) were dissolved in distilled water. Reagents were treated at the time of medium change. DMSO was treated as a control vehicle. 
Flow Cytometry Analysis

Mitochondrial Function Assays
Mitochondrial assays were performed at day 10. 
Electron Microscopic Analysis of H9C2 Cells
The cells were fixed in 2.5% glutaraldehyde in PBS solution at 4°C overnight, and then with 1% osmium tetroxide in PBS for 2 hour. The tissues were washed, dehydrated, and embedded, and then semi-thin sections were cut (0.5 to 1 lm). Further ultra-sectioning (60 to 90 nm) was performed and then the slices were double stained with uranyl acetate and lead citrate and imaged using a JEM 1200 EX2 electron microscope (Jeol). Developed images were scanned on a flatbed scanner (Umax PowerLook 1100) and analyzed using Image J software (http://imagej.nih.gov/ij/, 1.47V, NIH).
Quantitative Real Time PCR
Total RNA was extracted using Trizol RNA extraction kit (Invitrogen) according to the manufacturer's instructions. Total RNA was reverse transcribed into cDNA using GoScript TM cDNA synthesis system (Promega). cDNA was applied for quantitative real-time PCR using FastStart SYBR Green Master mix (Roche) and Bio-rad S1000 Thermocycler with the indicated primers ( Table 1) . Betaactin was used as a reference gene and the results were presented as relative expression to control using the DDCt method.
Measurement of Oxygen Consumption
After the cells were harvested, oxygen consumption rates (OCR) were measured using NeoFox Phase Measurement system (Ocean Optics) with a 400 lL chamber at room 
ATP Assay
ATP concentration was analyzed by ATP bioluminescent somatic cell assay kit (Sigma). In brief, 100 lL of ATP assay mix working solution, 100 lL of somatic cell ATP releasing reagent, and 50 lL of ultrapure water were added and mixed in each of the assay vials. Cells were harvested and then 1910 5 cells were added to each assay vials. Luminescence was detected by SpectraMax M2 (Molecular device). ATP concentration was calculated by using standard curve with known concentration (0, 10, 100, and 200 lmol/L) of ATP standard.
Measurement of ROS Levels
ROS levels were measured by 2 0 ,7
In brief, cells were loaded with 1.5 lmol/L of fluorescent dye for 30 minutes at 37°C in PBS. Then, the cells were harvested with 0.25% trypsin-EDTA and washed using PBS/2% FBS twice. The cell pellets were re-suspended in 400 lL PBS/2% FBS and analyzed by flow cytometry. Data were analyzed using FlowJo Version 7.5.4 software (TreeStar).
Electrophysiology
We performed the patch clamp study at day 14.5 after aMHC-GFP + cardiomyocyte FACS sorting. Action potentials (APs) and ion currents were recorded from beating cardiomyocytes placed onto the recording chamber of microscope by using Axopatch 200B amplifier (Axon Instrument) at room temperature (23AE1°C). Patch clamp recordings were carried out in whole-cell configuration where normal Tyrode (NT) solution was used for perfusion of cardiomyocytes and a K + -rich solution was used for pipette filling. Patch pipettes were pulled from thin-walled borosilicate capillaries (Clark Electromedical Instruments) using a PP-83 vertical puller (Narishige). GΩ seal formation and membrane rupture were achieved by applying negative pressure onto the membrane patch and only whole-cell patches with series resistance <5 MΩ were selected for recording. All the recordings were carried out at least 5 minutes after achieving whole-cell configuration to allow cells being completely dialyzed with pipette-filling solution. Spontaneous APs were recorded in current-clamp mode while ion currents were recorded in voltage-clamp mode. The voltage and current signals were filtered at 10 kHz, 4-pole Bessel type low-pass filter and sampled at a rate of 4 kHz for voltage and 27 kHz for ion current. All experimental parameters, such as pulse generation and data acquisition, were controlled using our own software (PatchPro). The liquidjunction potentials between bathing and pipette filling solution, which were calculated based on ionic mobility, were <5 mV. Kharche's model 39 was employed and modified to simulate 3 different types of AP in ESC-derived aMHC-GFP + cardiomyocytes.
Statistical Analysis
Values presented are meansAEstandard deviation (SD). The assumption of normality was evaluated using Shaprio-Wilk test. Significant differences between means were determined by unpaired Student t test or analysis of variance with 1-way ANOVA followed by the StudentNewman-Keuls test. The Mann-Whitney test and KruskalWallis ANOVA were performed when data were not normally distributed. Statistical significance was set at P<0.05 or 0.01.
Results
CsA Promotes Differentiation and Expansion of Cardiomyocytes From Flk1 + MPCs Derived From Mouse PSCs in OP9 Co-Culture System
To monitor cardiomyocyte differentiation in a live condition, we used mouse EMG7 ESC line, 11 which has a transgene of cardiac specific aMHC promoter-driven enhanced GFP. At day 4.5 after the start of mesodermal induction without LIF in the ESCs, Flk1 + MPCs were sorted and were co-cultured with MMC-treated OP9 feeder cell layer in differentiation medium, 11 and the cardiomyocyte differentiation was analyzed at day 10.5 unless otherwise indicated ( Figure 1A ). Self-beating cardiomyocytes, aMHC-GFP + and cTnT + appeared at day 8.5 ( Figure 1B and 1C) , and almost maximally expanded until day 10.5. In range of 0.5 to 4 lg/mL of CsA, 2 lg/mL of CsA showed the maximal effects on differentiation and expansion of cardiomyocytes ( Figure 1D and 1E). In fact, 2 lg/mL of CsA (hereafter named as CsA) increased number of self-beating foci (8.6-fold), aMHC-GFP + area (12.8-fold) , and the population of cTnT + cardiomyocytes (%7-to 9-fold) compared with control vehicle ( Figures 1F through 1M , Videos S1 and S2). CsA also increased the population of cTnT + cardiomyocytes (2.9-fold) from the mouse iPSCs ( Figures 1N and 1O ). In contrast, CsA reduced differentiation of ECs (26.0%) and HCs (14.4%) (Figures 2A through 2F ). Interestingly, CsA was superior to previously known cardiomyocyte differentiation agents including Wnt signaling inhibitors IWP-2 and IWP-4, and transforming growth factor beta (TGFb) signaling inhibitor SB431542 in the cardiomyocyte differentiation and expansion ( Figures 2G and 2H ). These findings led us to investigate how CsA promotes differentiation and expansion of cardiomyocytes (hereafter called "cardiomyogenic effect") from the PSC-derived Flk1 + MPCs.
The Cardiomyogenic Effect of CsA Mainly Resulted From mPTP Inhibition Rather Than From Calcineurin Inhibition
CsA binding to calcineurin results in its well-known immunosuppressive effect through the nuclear factor of activated Con CsA
(4) 
T-cells (NFAT)
. 18 Another target protein for CsA is cyclophilin D, which is the matrix protein component of mPTP. 18 To delineate how CsA induces the cardiomyogenic effect, we compared the effects of CsA with FK506, which blocks calcineurin activity via its receptor FKBP12 but has no effect on mPTP and NIM811, which blocks mPTP but has no effect on calcineurin. 18 Compared with control vehicle, NIM811 (3.6 lg/mL) increased the cTnT + cardiomyocyte population (6.8-fold), whereas FK506
(100 ng/mL) only slightly increased the cTnT + cardiomyocyte population (2.0-fold). Treatment of both NIM811 and FK506 showed an additive effect in increasing the cTnT + cardiomyocyte population (9.0-fold) ( Figures 3A and 3B) . Accordingly, NIM811 markedly increased the number of self-beating foci (10.5-fold) and aMHC-GFP + area (12.4-fold), whereas FK506
had only minor effects (3.3-fold and 2.7-fold) (Figures 3C through 3F and Videos S3 and S4). Thus, the cardiomyogenic effect of CsA was mainly due to mPTP inhibition rather than calcineurin inhibition.
Inhibition of mPTP by CsA Directly Increases Mitochondrial Function, Which is Closely Related to Cardiomyogenesis
To alternatively confirm the inhibition of mPTP by CsA, a CoCl 2 /Calcein AM quenching method 38 4G ). These data suggest that CsA directly increases mitochondrial function in PSC-derived cardiomyocytes. Additionally, Dw m of differentiating ESCs in day 4.5 is lower than in day 10.5 ( Figure 4H ). These data indicate that mitochondrial function is increased during cardiomyocyte differentiation from ESCs. Next, we examined the mRNA expression levels of the genes related to mitochondrial function (pgc1a, ppara and nrf1) and cardiomyocyte differentiation (tbx5, nkx2.5 and tnnt2) in the differentiating Flk1 + MPCs. The expression levels of all these genes were variably up-regulated by CsA compared with control vehicle (Figure 4I ), suggesting that CsA regulates the cardiomyogenic effect by alterations of the gene transcriptions related to mitochondrial function.
Observation of individual cardiomyocytes after FACS sorting using aMHC-GFP revealed that the shape, beating rate, mitochondria content, and cTnT + sarcomere structure of each cardiomyocyte was quite varied (Video S5, Figure 5A ). Interestingly, cardiomyocytes with loosely organized sarcomere structure also showed less developed, fragmented mitochondria that are located in the perinuclear region ( Figure 5A-1 and 5B-1), while cardiomyocytes with densely organized sarcomere structure contained well-developed, elongated mitochondria which are distributed along the sarcomere ( Figures 5A-2 and 5B-2). These data indicate that mitochondrial development and function are closely related to cardiomyogenesis.
To confirm whether the effect of CsA to mitochondria in differentiating Flk1 + MPCs is a direct effect rather than a secondary effect due to cardiomyogenesis, we treated CsA Figures 6E and 6F) . Additionally, electron microscope images revealed that CsA increased the mitochondrial size (1.7-fold) and yielded more matured cristae structure ( Figures 7A and  7B ). These data suggest that an increase of mitochondrial function is a direct effect of CsA rather than a secondary effect due to cardiomyogenesis in differentiating Flk1 + MPCs.
Activation of Mitochondrial Oxidative Metabolism via mPTP Inhibition Promotes Cardiomyogenesis
The aforementioned findings led us to investigate whether CsA has an effect on activation of mitochondrial oxidative metabolism by measurements of OCR and ATP levels. 41 Compared with control vehicle, CsA increased the OCR and ATP levels in the differentiating Flk1 + MPCs (1.7-fold and 6.6-fold respectively) and H9C2 cardiac cell line (2.0-fold and 4.9-fold respectively) (Figures 8A through 8C and 8F through 8H), suggesting that CsA directly activates mitochondrial oxidative metabolism through mPTP inhibition. Addition of FCCP (3 lmol/L), an uncoupler of mitochondrial oxidative phosphorylation, reduced the CsA-induced cardiomyogenic effect by 54.5%, while FCCP alone did not significantly change the cardiomyocyte differentiation ( Figures 8D and 8E ). This result clearly indicates that the CsA-induced cardiomyogenic effect is partially caused by activation of mitochondrial oxidative metabolism.
Dual Modulation of mPTP and Redox Signaling Synergistically Promotes Cardiomyogenesis
mPTP inhibition by CsA or NIM811 increased ROS generation during cardiomyocyte differentiation ( Figure 9A ). Therefore, to confirm the role of redox signaling for cardiomyocyte differentiation under mPTP inhibition, we added either the antioxidants Trolox (100 to 1600 lmol/L, water-soluble analog of vitamin E) or NAC (100 to 1600 lg/mL), or the pro-oxidant tBHP (2 to 32 lmol/L) with CsA. Surprisingly, the addition of either Trolox or NAC synergistically enhanced the CsA-induced cardiomyogenesis (160.6% to 330.5% or 144.9% to 239.7%) in a dose-dependent manner, while Trolox or NAC alone did not significantly enhance the cardiomyocyte differentiation ( Figures 9B and 9C ) even though the antioxidants indeed blunted the ROS levels ( Figure 9E) . However, the addition of pro-oxidant tBHP did not enhance the cardiomyocyte differentiation, regardless of CsA treatment ( Figures 9C  and 9D ) even though it exhibited the pro-oxidant effect ( Figure 9F ). These results indicate that the cardiomyogenic effect of antioxidants is dependent on CsA, and that the redox signaling is a cardiomyogenesis regulatory factor lying downstream of mPTP inhibition. In addition, these data suggest that the reduction of ROS and oxidative stress is critical for efficient cardiomyogenesis under mPTP inhibition. 
Cardiomyocyte Induced by CsA has Electrophysiologically Functional Properties
To examine whether the single beating aMHC-GFP + cardiomyocytes, induced by CsA (Video S5) indeed retain APs and ion currents characteristic of a cardiomyocyte, whole-cell patch clamp recordings were carried out in both currentclamp and voltage-clamp modes. Constant and robust firings of spontaneous APs were identified from 16 different cardiomyocytes ( Figures 10A through 10C ). All the results are summarized in Table 2 . Among the types of AP, the nodal type was most frequently recorded according to our criteria ( Figure 10D ). To identify whether those beating cardiomyocytes have functional ion currents, voltage-clamp recordings were carried out in various pulse protocols. Depolarizing test pulses between À30 and +50 mV from a holding potential of -40 mV induced large inward currents ( Figure 10E ). The current-voltage (IV) relation curve was bell shaped with its peak at 0 mV, which is typical of L-type Ca 2+ currents.
Hyperpolarizing test pulses between À130 and À60 mV induced slowly developing inward currents ( Figure 10F ). The extrapolation of IV relation indicates the reversal potential is similar to that of hyperpolarization activated current (I HCN ). Depolarizing test pulses between À70 mV and +50 mV from a holding potential of À80 mV induced either rapidly activating ( Figure 10G ) or slowly developing ( Figure 10H ) outward currents, which are considered to be transient outward K + current (I to ) or slowly activating delayed rectifier K + current (I Ks ). These results indicate that ESC-derived cardiomyocytes induced by CsA are electrophysiologically functional cardiomyocytes. Simulation was also carried out as shown in right panel of each Figure 10 (indicated as blue) to gain insight into which ion channels are responsible for differentiation of APs among cardiomyocytes. Our simulation study suggests that the difference in inactivation kinetics of Ltype Ca 2+ -channel among cardiomyocytes might be a key determinant for their different shapes of APs.
CsA Promotes Cardiomyogenesis From Mouse and Human ESCs in Feeder-Free Condition
To examine whether CsA can exert its cardiomyogenic effect independently of OP9 feeder cells, we treated CsA to both feeder-free ESC monolayer and EBs during mouse ESC differentiation. Only few (2.4% in the monolayer and 1.7% in the EBs) cTnT + cardiomyocytes were detected in control vehicle group. On the other hand, CsA increased the area of aMHC-GFP + (2.2-fold) and the percentages of cTnT + cardiomyocytes (2.0-fold) in the monolayer, while it increased the area of aMHC-GFP + (3.7-fold) and the percentages of cTnT + cardiomyocytes (2.0-fold) in the EBs (Figure 11A through 11J) .
CsA also increased the area of self-beating cardiomyocytes in the EBs compared to control vehicle (Videos S6 and S7). Moreover, CsA expanded the area (3.5-fold) and percentages (2.2-fold) of cTnT + cardiomyocytes in the differentiating human ESCs (Figures 11K through 11O ). These data indicate that CsA is directly capable of promoting cardiomyogenesis in both mouse and human PSCs.
Discussion
Obtaining ample differentiated cardiomyocytes from PSCs with a simple and efficient method is a critical component in achieving stem cell therapy for cardiac regeneration. To date, various small molecules for cardiomyogenesis have been tested, most of which are related to signaling pathways such as BMP, TGFb, activin, nodal, Wnt, and FGF. transplantation rejection, CsA by comparison intriguingly promotes the differentiation of cardiomyocytes from PSCs. 15, 16 Here, we demonstrate that the effect of CsA in cardiomyogenesis from PSCs mainly results from mPTP inhibition rather than from calcineurin inhibition. mPTP is an emerging therapeutic target for treating pathologic conditions including cardiac and neurodegenerative diseases. 18 Pathologic conditions such as oxidative stress and calcium overload can trigger the opening of the mPTP, which leads to the collapse of Dw m followed by ATP depletion, mitochondrial swelling, and ultimately cell death. 18 In fact, mPTP inhibition by CsA has a cardioprotective effect in ischemia-reperfusion injury in both animal studies 18, 43 and clinical trial. 44 However, only a few mitochondria, which aids in the differentiation of cardiomyocytes; these results are similar to our findings, but are based on work with primary cultured cardiomyocytes derived from embryonic heart. 45 Thus, our findings from PSC-derived cardiomyocytes present a practical possibility in the field of regenerative medicine. This study also demonstrates that mPTP inhibition by CsA directly increases mitochondrial function in differentiating Flk1 + MPCs and H9C2 cardiac cells, and that the mitochondrial function determines the fate of Flk1 + MPCs toward the cardiac lineage. In a mature heart, mitochondrial oxidative metabolism is a major source of energy. In contrast to mature cardiomyocytes, energy metabolism during cardiomyocyte development is altered along with the progression of differentiation. 46 During differentiation from undifferentiated ESCs to differentiated cardiomyocytes, mitochondrial function and morphology undergo dramatic changes; in particular, cellular energy metabolism switches from glycolysis to mitochondrial oxidative metabolism. 20, 47 Morphologically, previous studies and our data show that mitochondria in ESCs or immature cardiomyocytes are spherical and located in the perinuclear area with poorly developed cristae, but become elongated and relocate to the cytoplasm with abundant and organized cristae in mature cardiomyocytes. 20, 45 In addition, mitochondrial biogenesis and oxidative metabolism-related genes are increased during cardiomyocyte development. 48 These find- ings might be considered as a consequence, rather than a cause of cardiomyocyte differentiation, merely reflecting increasing contraction and thus the metabolic demands of cardiomyogenesis. However, some evidence suggests that mitochondrial development precedes cardiomyogenesis, and that mitochondrial function and maturation control cardiomyogenesis. A previous study showed that the induction of mitochondrial biogenesis begins shortly before cardiomyocytes beat during EB differentiation. 40 Furthermore, the differentiation potential of cardiac progenitors into cardiomyocytes relies on mitochondrial content and the capacity for oxidative metabolism. 24 Hom et al reported that inhibition of mPTP promotes mitochondrial maturation, which supports cardiomyocyte differentiation in primary cultured cardiomyocytes derived from embryonic heart. 45 Our data show that mPTP inhibition by CsA also increases mitochondrial oxidative metabolism and thus cardiomyocyte differentiation; on the other hand, the addition of FCCP with CsA significantly reduces cardiomyocyte differentiation from PSCs. Recently, it was shown that mitochondrial fusion directs cardiomyocyte differentiation via Ca 2+ , calcineurin, and Notch signaling, independently of mitochondrial function. 49 Therefore, the minimal cardiomyogenic effect of calcineurin inhibition in our data might be related to mitochondrial dynamics and Notch signaling. Taken together, the results of previous reports and our data indicate that mitochondria-related signaling has direct implications for cardiomyogenesis and stem cell fate determination. Our data collectively showed that antioxidants enhance the cardiomyogenic effect of CsA. ROS are important regulators of intracellular signaling 50 and regulate the differentiation of ESCs into cardiomyocytes. Many previous groups have reported that ROS generated from NADPH (nicotinamide adenine dinucleotide phosphate) oxidases mediate cardiomyocyte differentiation [26] [27] [28] 30 while antioxidant treatment inhibits cardiomyocyte differentiation from ESCs, 26, 28, 51 in contrast with our findings. However, one study suggested that valproic acid, which significantly induces ROS generation, delays cardiomyocyte differentiation while further treatment with antioxidant treatment restores it. 52 Recent work indicates that antioxidant treatment promotes myocyte differentiation from primary cultured cardiomyocytes derived from embryonic heart while pro-oxidant treatment inhibits it. 45 The most recent report showed that lowering ROS levels increases the Ca 2+ transient amplitude, like mature adult cardiomyocyte in human ESC-derived cardiomyocyte. 53 These conflicting findings might depend on cell type and ROS levels: relatively modest concentrations of ROS promote cardiomyogenesis, while high or low concentrations inhibit it. 31, 32, 50, 54 Our results showed that antioxidant with CsA treatment A B Figure 12 . Schematic diagram of mitochondrial metabolic and redox signaling pathways during cardiomyocyte differentiation. A, During differentiation from Flk1 + MPCs to cardiomyocytes, cellular metabolism is changed from glycolysis to oxidative phosphorylation. CsA binds to cycophilin D which is a mitochondrial matrix protein that inhibits mPTP. Inhibition of mPTP activates the mitochondrial oxidative metabolism and promotes cardiomyocyte differentiation from Flk1 + MPCs. Addition of antioxidant with CsA profoundly augments cardiomyocyte differentiation. B, Estimation and comparison of the absolute number of cardiomyocytes generated from one ESC differentiated under control vehicle, CsA and CsA with antioxidants treatment. CsA indicates cyclosporin A; ESC, embryonic stem cell; IMM, inner mitochondrial membrane; MPCs, mesodermal precursor cells; mPTP, mitochondrial permeability transition pore; OMM, outer mitochondrial membrane; PSC, pluripotent stem cell; ROS, reactive oxygen species.
augmented cardiomyogenesis but that antioxidants alone or supplementing with a pro-oxidant did not yield any significant changes. Our interpretation of these findings is that mPTP inhibition by CsA increases mitochondrial oxidative metabolism that induce cardiomyogenesis and the generation of ROS, but that a reduction of ROS and oxidative stress is also critical for efficient cardiomyogenesis under mPTP inhibition ( Figure 12A) . 32, 50, 54 Taken together, our results show that the activation of mitochondrial oxidative metabolism via mPTP inhibition by CsA enhances differentiation of functional cardiomyocytes from PSCs. We also found that antioxidant treatment augments the cardiomyogenic effect of CsA. Because CsA and antioxidants are widely used in clinical practice, supplementation of CsA and antioxidants would be a simple, efficient, and safe method for obtaining an ample amount of PSC-derived cardiomyocytes ( Figure 12B ). Additionally, these data provide new insights into the mitochondrial metabolic and redox signaling pathways that are crucial targets for cardiac stem cell therapy in the field of regenerative medicine. 
